Illumina Launches VeriSeq PGS

  Illumina Launches VeriSeq PGS

  Next-Generation Sequencing Solution for Preimplantation Genetic Screening
                         Offers Increased Scalability

Business Wire

SAN DIEGO -- April 29, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of VeriSeq^TM PGS, a
next-generation sequencing (NGS) solution developed for preimplantation
genetic screening (PGS) of embryos using Illumina’s NextSeq^TM 500 and MiSeq®
sequencing systems. The offering brings together the industry-leading Illumina
24sure array-based platform for PGS with Illumina’s next-generation sequencing
(NGS) technology to offer laboratories a more scalable PGS solution.

“Bringing the high-throughput capabilities of Illumina’s NGS systems to PGS
will enable IVF clinics to offer the latest technology to their patients,”
said Simon Fishel, CEO of CARE Fertility Group. “VeriSeq PGS has the potential
to improve pregnancy success rates for couples using IVF by identifying
chromosomally normal embryos for implantation.”

PGS has been clinically proven as an effective means to select chromosomally
normal embryos, increasing pregnancy success rates for in vitro fertilization
(IVF) procedures.^1,2 VeriSeq PGS complements the 24sure array-based assay,
using the same sample preparation and BlueFuse software workflows. The
NGS-based assay leverages Illumina’s sequencing systems and enables reference
laboratories to perform PGS using a platform that meets their throughput
needs.

“VeriSeq PGS showed a high level of consistency with the established 24sure
technology,” said Francesco Fiorentino, Ph.D., Founder and Lab Director,
GENOMA Laboratory. “I recently did a comparison study between the 24sure assay
and VeriSeq PGS to assess the accuracy of an NGS-based test for aneuploidy
screening on single cells. NGS-based aneuploidy screening appears to be a
robust methodology ready to find a place in routine clinical application.”

“VeriSeq PGS demonstrates Illumina’s continuing commitment to reproductive and
genetic health. By developing and providing accessible tools to perform PGS,
we hope to enable reference laboratories to offer these services worldwide,”
said Tristan Orpin, Senior Vice President and General Manager of Reproductive
and Genetic Health for Illumina. “We want to offer these groups a complete
reproductive health portfolio so they can better support physicians and their
patients in pursuit of successful pregnancies.”

The new VeriSeq PGS solution on the MiSeq sequencing system will begin
shipping in June, and the solution for the NextSeq 500 sequencing system will
begin shipping later in 2014. For more information, visit
www.illumina.com/VeriSeqPGS.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

^1 Yang Z, Liu J, Collins GS, Salem SA, Liu X, et al. (2012) Selection of
single blastocysts for fresh transfer via standard morphology assessment alone
and with array CGH for good prognosis IVF patients: results from a randomized
pilot study. Mol Cytogenet 5(1): 24.

^2 Harton GL, Munné S, Surrey M, Grifo J, Kaplan B, et al. (2013) Diminished
effect of maternal age on implantation after preimplantation genetic diagnosis
with array comparative genomic hybridization. Fertil Steril 100(6): 1695–1703.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.